Last reviewed · How we verify
clofibrate clofibrate — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
clofibrate clofibrate (clofibrate clofibrate) — National Heart, Lung, and Blood Institute (NHLBI). Clofibrate activates peroxisome proliferator-activated receptor alpha (PPAR-α) to increase lipoprotein lipase activity and reduce triglyceride levels.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| clofibrate clofibrate TARGET | clofibrate clofibrate | National Heart, Lung, and Blood Institute (NHLBI) | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- clofibrate clofibrate CI watch — RSS
- clofibrate clofibrate CI watch — Atom
- clofibrate clofibrate CI watch — JSON
- clofibrate clofibrate alone — RSS
Cite this brief
Drug Landscape (2026). clofibrate clofibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/clofibrate-clofibrate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing